MyFinsight
Home
Blog
About
Contact
Download
Download image
Total comprehensive
loss
-$22,682K
(56.17%↑ Y/Y)
Collaboration Revenue
$243,566K
Product
$159,569K
Net loss
-$22,682K
(56.17%↑ Y/Y)
Total revenues
$403,135K
(21.31%↑ Y/Y)
Loss before income
taxes
-$20,841K
Provision for taxes on
income
$1,841K
Income (loss) from
operations
$60,273K
(10.79%↑ Y/Y)
Other income, net
$3,490K
(-56.49%↓ Y/Y)
Total operating
expenses
$342,862K
(23.37%↑ Y/Y)
Interest expense
$84,604K
(42.79%↑ Y/Y)
Selling, general and
administrative
$165,786K
(1.66%↑ Y/Y)
Cost of goods sold
$129,224K
(88.37%↑ Y/Y)
Research and development
$47,852K
(3.49%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)